We have previously shown changes in behavior, specifically in hippocampus-dependent associative learning, in these mice under healthy conditions [7], which support further the idea that caution is needed when using non-selective inhibitors of NF-κB activity to treat MS, as they might affect cognition of the patients as a side effect. The gene discussed is NFKB1; the disease is myeloid sarcoma.